Tangible Material: Capan-1: Human Pancreatic Adenocarcinoma Cell Line

SK 923

Description

Capan-1 is a human pancreatic ductal adenocarcinoma cell line. These cells grow in adherent tissue culture and display epithelial morphology. In culture, these cells are capable of invading through an extracellular matrix, such as Matrigel. The Capan-1 cells are resistant to 5-fluorouracil, reminiscent of the original tumor from which they were derived. They form poorly-differentiated tumors when injected into immunocompromised mice. These cells harbor a single base-pair deletion in the BRCA2 allele, which results in the expression of a truncated and dysfunctional protein. In addition, they have an oncogenic mutation in K-Ras (G12V) and an inactivating mutation in p53. These cells express elevated levels of the Epidermal Growth Factor Receptor (EGFR) and do not express SMAD4 protein (i.e., SMAD4-null). The Capan-1 cells are useful both as a xenograft model for pancreatic cancer and as a cell system to study the effects of BRCA2-deficiency.

Source

This cell line was established in 1974 from a metastatic site (liver) in a 40-year-old Caucasian male with pancreatic ductal adenocarcinoma.

Inventors

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Kyriazis AP et al. (1982) Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. American Journal of Pathology 106: 250-260 (PubMed ID: 6278935)
  • Deer EL et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435 (PubMed ID: 20418756)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes. 

Contact Information

Tingting Zhang-Kharas, PhD
Licensing Assistant
Tel: 646-888-1083; Fax: 646-888-1120

 

Stage of Development
Ready to use
Technology Types
Indications